$41.90
3.28% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
CA98420N1050
Symbol
XENE

Xenon Pharmaceuticals Inc. Stock price

$41.90
+5.91 16.42% 1M
+8.87 26.85% 6M
+2.70 6.89% YTD
+1.19 2.92% 1Y
+7.14 20.54% 3Y
+30.96 283.00% 5Y
+32.26 334.65% 10Y
+31.40 299.05% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+1.33 3.28%
ISIN
CA98420N1050
Symbol
XENE
Industry

Key metrics

Basic
Market capitalization
$3.2b
Enterprise Value
$2.7b
Net debt
positive
Cash
$487.6m
Shares outstanding
76.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
428.0 | 418.0
EV/Sales
363.0 | 354.5
EV/FCF
negative
P/B
5.1
Financial Health
Equity Ratio
94.6%
Return on Equity
-31.0%
ROCE
-49.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.5m | $7.7m
EBITDA
$-315.5m | $-366.4m
EBIT
$-318.1m | $-367.6m
Net Income
$-278.2m | $-333.5m
Free Cash Flow
$-233.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-35.0% | -32.4%
EBIT
-33.9% | -31.6%
Net Income
-39.8% | -42.3%
Free Cash Flow
-48.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,207.0% | -4,770.5%
EBIT
-4,241.6%
Net
-3,709.7% | -4,342.3%
Free Cash Flow
-3,106.5%
More
EPS
$-3.5
FCF per Share
$-3.0
Short interest
11.1%
Employees
322
Rev per Employee
$0.0
Show more

Is Xenon Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Xenon Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

24x Buy
96%
1x Hold
4%

Analyst Opinions

25 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

Buy
96%
Hold
4%

Financial data from Xenon Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
7.50 7.50
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 73 73
22% 22%
973%
- Research and Development Expense 253 253
42% 42%
3,368%
-316 -316
35% 35%
-4,207%
- Depreciation and Amortization 2.59 2.59
33% 33%
35%
EBIT (Operating Income) EBIT -318 -318
34% 34%
-4,242%
Net Profit -278 -278
40% 40%
-3,710%

In millions USD.

Don't miss a Thing! We will send you all news about Xenon Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenon Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of ...
Neutral
Seeking Alpha
9 days ago
Xenon Pharmaceuticals Inc. - Special Call Company Participants Ian Mortimer - Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director James Empfield - Executive Vice President of Drug Discovery JP Gilbert Christopher Kenney - Chief Medical Officer Presentation Ian Mortimer Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Of...
Neutral
GlobeNewsWire
20 days ago
VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs target...
More Xenon Pharmaceuticals Inc. News

Company Profile

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Head office Canada
CEO Ian Mortimer
Employees 322
Founded 1996
Website www.xenon-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today